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The main function of our immune system is to protect us from invading pathogens and microorganisms by destroying infected
cells, while minimizing collateral damage to tissues. In order to maintain this balance between immunity and tolerance, current
understanding of the immune system attributes a major role to regulatory T cells (Tregs) in controlling both immunity and toler-
ance. Various subsets of Tregs have been identiﬁed based on their expression of cell surface markers, production of cytokines, and
mechanisms of action. In brief, naturally occurring thymic-derived CD4+CD25+ Tregs are characterized by constitutive expres-
sion of the transcription factor FOXP3, while antigen-induced or adaptive Tregs are mainly identiﬁed by expression of immuno-
suppressive cytokines (interleukin-10 (IL-10) and/or transforming growth factor-β (TGF-β)). While Tregs in normal conditions
regulate ongoing immune responses and prevent autoimmunity, imbalanced function or number of these Tregs, either enhanced
or decreased, might lead, respectively, to decreased immunity (e.g., with tumor development or infections) or autoimmunity (e.g.,
multiple sclerosis). This review will discuss recent research towards a better understanding of the biology of Tregs, their interaction
with other immune eﬀector cells, such as dendritic cells, and possible interventions in human disease.
Copyright © 2007 Nathalie Cools et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The main function of our immune system is to protect us
from invading pathogens and microorganisms by destroying
infected cells, while minimizing collateral damage to tissues.
Within the large pool of diﬀerent immune eﬀector cells, the
recently rediscovered regulatory T cells (Tregs) play an im-
portant role in controlling immune responses and silencing
self-reactive T cells.
2. ORIGIN AND SUBSETS OF REGULATORY T CELLS
Tregs were described for the ﬁrst time in the early 1970s
and were called suppressor cells [1, 2]. Despite many ef-
forts, this research topic was abandoned in the late 1980s
due to diﬃculties in correctly identifying and isolating the
suppressor cells. In 1995, Sakaguchi et al. [3] showed that
the interleukin-2 receptor α-chain (CD25) could serve as a
phenotypic marker for CD4+ Tregs. These observations led
to the revival of Tregs, and this research ﬁeld has evolved
rapidly ever since. Currently, various subsets of both CD25+
and CD25− Tregs populations have been described [4] (see
Table 1).DiﬀerentTregssubsetsarenowsubdividedbasedon
expression of cell surface markers, production of cytokines,
and mechanisms of action.
Naturally occurring thymic-derived CD4+CD25+ Tregs
are a T cell population with immunosuppressive proper-
ties that constitutes 5–10% of the total peripheral CD4+
T cells [5, 6]. Besides the expression of CD25, they con-
stitutively express other several activation markers, such
as the glucocorticoid-induced tumor-necrosis factor (TNF)
receptor-related protein (GITR), OX40 (CD134), L-selectin
(CD62 ligand (CD62L)), and cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4 or CD152). However, it should
be noted that none of these markers exclusively identiﬁes
Tregs as they can also be expressed to various degrees on
activated T cell subsets and various antigen-presenting cells
(APCs).Morerecentstudieshaveidentiﬁedthetranscription
factor forkhead box P3 (FOXP3) as a more exclusive intra-
cellular marker for the identiﬁcation of Tregs [7, 8]. In ad-
dition, FOXP3 is also a crucial transcription factor for the
development and functionality of CD4+CD25+ Tregs. Loss2 Clinical and Developmental Immunology
of function mutations in FOXP3, both in mice and men, re-
sults in the absence of Tregs, leading to a phenotype with
severe autoimmune disorders [9, 10], known as scurfy mice
and IPEX (immunedysregulation, polyendocrinopathy, en-
teropathy, X-linked syndrome) in men. The important func-
tion of FOXP3 was also conﬁrmed by studies showing that
ectopic expression of FOXP3 in T cells leads to the gener-
ation of cells with a regulatory phenotype and a suppres-
sive function [7, 11]. In addition, with regard to the biolog-
ical function of FOXP3 in Tregs, it was demonstrated that
FOXP3 blocks the ability of the Rel-family transcription fac-
tors NFAT and NFκB to induce their target genes [12–14],
and as a consequence, it acts as a transcriptional repressor
of IL-2 and other cytokine genes (IL-4 and IFN-γ), thereby
programming a cell not to exert immune stimulatory func-
tions. Moreover, FOXP3 expression has also been demon-
stratedinactivatedTcellsinhumans[15],presumablyacting
as a negative feedback in order to control ongoing immune
responses.
There is still ongoing discussion whether CD4+CD25+
Tregs originate in the thymus and constitute a separate lin-
eage or they are generated from mature T cells in the periph-
ery. Most likely, both origins seem to play an important role.
During early life, Hassall’s corpuscules, epithelial substruc-
tures in the thymus, play an important role in the generation
of Tregs [16, 17]. In addition, the expression of FOXP3 as a
Treg lineage speciﬁcation factor [18] also supports the no-
tion that Tregs are a separately derived T cell lineage. More-
over, neonatal mice that have undergone thymectomy spon-
taneously develop autoimmune diseases [19, 20]. On the
other hand, while thymic function is largely reduced after
puberty in man, Tregs persist throughout life. This implies
that (all) Tregs might originate from a pool of self-renewable
long-term surviving thymic emigrants. However, Akbar et
al. [21] recently showed that the number and function of
CD4+CD25+FOXP3+ Tregs are maintained in humans even
after the age of 70 years. Therefore, they suggested that these
cells most probably do not derive from the thymic lineage
of Tregs, but they are generated from the peripheral pool of
CD4+CD45RO+CD25−FOXP3− memory T cells.
Furthermore, several other studies also reported the exis-
tenceofvarioussubsetsofantigen-inducedoradaptiveTregs.
The suppressive function of these induced Tregs is mediated
by the production of suppressive cytokines (IL-10 and trans-
forming growth factor-β (TGF-β)). Therefore, the current
classiﬁcation of induced Tregs is based on expression of dif-
ferent suppressive cytokines. CD4+ regulatory T cells of type
1( T r 1 )e x p r e s sh i g hl e v e l so fI L - 1 0a n dm o d e r a t el e v e l so f
IL-5, IFN-γ,a n dT G F - β, and they are negative for IL-2 and
IL-4[22,23].Thelper3(Th3)r egulat oryTc ellse xpr esshigh
levels of TGF-β [24, 25]. Both types of induced Tregs equally
suppress Th1− as well as Th2− mediated immune responses.
Tr1 and Th3 have been shown to originate from naive rest-
ing T cells after stimulation with dendritic cells (DCs) [26],
depending on DC type and activation status. In addition,
naturally occurring Tregs are also involved in the genera-
tion of induced Tregs, a mechanism proposed as “infectious
tolerance.” The latter is based on expression of certain in-
tegrins by naturally occurring CD4+CD25+FOXP3+ Tregs
[27]. While α4β7 integrin expression induces IL-10 produc-
ing Tr1 cells, α4β1 integrin expression induces TGF-β pro-
ducingTh3cells.Furthermore,wehaverecentlydescribedan
additional population of TGF-β and IL-10 double-positive
CD4+CD25−FOXP3− adaptive Tregs [28], induced after in
vitro culture of peripheral blood lymphocytes (PBLs) with
immatureandmatureDCs.Moreover,thesuppressivecapac-
ity of this CD4+ T cell population was transferable to already
activated antigen-speciﬁc CD8+ T cells when CD4+ Tc e l l s
were conditioned by immature DCs, but not when CD4+ T
cells were conditioned by Toll-like receptor-3 (TLR3) ligand-
matured DCs.
NexttotheinvolvementofCD4+ naturallyoccurringand
induced Tregs in controlling proper function of the immune
system, CD8+ T suppressor cells have also been described.
CD8+ T suppressor cells are derived from an oligoclonal T
cell population, and they lack CD28 and express FOXP3,
GITR, CTLA-4, OX-40, and CD62L at the same level as com-
pared to CD4+CD25+ Tregs [29, 30]. In addition, CD8+ T
suppressor cells, that are able to inhibit T cell proliferation,
can be induced by xenogenic APCs or by peptide-pulsed au-
tologous APCs [31, 32].
Of note, a special population of natural killer (NK) cells
and NKT cells with regulatory function has also been de-
scribed. Their immune suppressive function is mediated by
secretion of various cytokines (IL-13, IL-4, IL-10) or by di-
rect cell-cell contact [33]. In this review, however, we will fo-
cus on the diﬀerent subsets of Tregs.
3. MECHANISMS OF SUPPRESSION
All Tregs, both naturally occurring and induced, need T
cell receptor (TCR) triggering for their suppressive function.
However, once activated, their suppressive activity seems
to be antigen-nonspeciﬁc [34]. To date, the precise mech-
anism(s) by which Tregs suppress eﬀector T cell activation
and/or function remains unclear. Moreover, results from
many in vitro and in vivo studies or studies performed on
mice and men are sometimes contradictory.
3.1. Cell-cellcontact
Several in vitro studies have demonstrated that CD4+CD25+
T r e g ss u p p r e s sp r o l i f e r a t i o na n dI F N - γ production by eﬀec-
tor T cells through a direct cell-cell contact-dependent stim-
ulation between suppressor and eﬀector cells, possibly medi-
ated by the expression of their cell surface markers GITR and
CTLA-4 [35]. Ligation of CD80/CD86 on eﬀector cells may
transmit suppressive signals after engagement by cell surface
CTLA-4 on suppressor cells, and it results in inhibition of
eﬀector T cell function (see Figure 1)[ 36]. Another mecha-
nism for Tregsto aﬀecteﬀectorTcellactivationcanbeestab-
lished by modulating DC function. Ligation of CD80/CD86
on DCs by CTLA-4 on suppressor cells results in expression
and activation of indoleamine 2,3-dioxygenase (IDO) [37],
a catabolic enzyme involved in tryptophan degradation. Re-
ducedtryptophanconcentrationinculturemediumhasbeen
reported to be associated with decreased activation of T cells
andTcelldeletion[38,39].Also,inseveralinvivomodelsforNathalie Cools et al. 3
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Figure 1: Possible mechanisms of suppression by regulatory T cells
(Tregs). Tregs mediate their suppressive action by direct cell-cell
contact mediated by CTLA-4 on both eﬀector T cells as well as
antigen-presenting cells (APCs), such as dendritic cells (DCs). Pro-
duction of immunosuppressive cytokines, such as IL-10 and TGF-
β, suppresses DC maturation, making DCs tolerogenic. Moreover,
Tregs can kill eﬀectorTcellsbyexpressionofperforinandgranzyme
A. The ﬁgure also indicates therapeutic action of the anti-CTLA-4
antibody.
disease disorders, it was demonstrated that CTLA-4 block-
ade abrogates the suppressive function of murine (e.g., in-
ﬂammatory bowel disease [40]) and human (e.g., melanoma
patients [41–44]) Tregs. These results indicate that CTLA-4
plays a functionally signiﬁcant role in Treg suppressive ac-
tivity. On the other hand, CTLA-4 knockout mice appear to
have cells that express the Treg-speciﬁc transcription factor
FOXP3 and that are capable of suppression [45, 46]. These
observations reveal that CTLA-4 is not the only accessory
molecule required for Treg function.
Indeed, cell surface-bound TGF-β has been reported to
mediate cell-cell contact-dependent immune suppression by
CD4+CD25+ Tregs [47]. However, the latter remains con-
troversial as functionally suppressive CD4+CD25+ Tregs can
be isolated from TGF-β deﬁcient mice [34]. In addition,
CD4+CD25− T cells transduced to express a dominant nega-
tive TGF-β receptor are still susceptible for Treg suppressive
activity. Moreover, inhibition of T cell proliferation in vitro
by IL-10 secreting Tr1 cells has been demonstrated to be in-
dependent of IL-10 production [48, 49]. Also O’Garra and
Vieira [50] postulated that the regulatory activity of IL-10
secreting Tregs might be in competition with eﬀector T cells
forAPCcontactorforsurvivalfactors(e.g.,IL-2).Therefore,
contact-dependent suppression mechanisms might be domi-
nant in vitro, circumventing the requirements for long-range
suppressive cytokines.
3.2. Solublefactors
While above described results suggest a contact-dependent
cytokine-independent mechanism of T cell suppression by
Tregs, other in vitro studies clearly demonstrate that Tr1 cells
and Th3 cells mediate their suppressive activity by produc-
ingimmunosuppressivecytokines,IL-10,andTGF-β,respec-
tively [51, 52]. Therefore, a deﬁnitive explanation regarding
the in vitro suppressive mechanism of Tregs remains un-
clear due to well-known limitations of in vitro cellular as-
says diﬀering in diﬀerent laboratories. However, several in
vivo studies have indicated the role of immune suppres-
sive cytokines in Treg-mediated activity. Their involvement
might be aﬀected by many physiological factors, including
the nature of the target organ and the magnitude of in-
ﬂammation. Indeed, some autoimmune diseases are caused
by IL-10 deﬁciency (e.g., colitis) [53, 54], whereas other
autoimmune diseases are IL-10-independent (e.g., gastritis)
[55] and/or -dependent on TGF-β deﬁciency (e.g., diabetes)
[56].Furthermore,CD4+CD25+ Tregs can be activated to ex-
press granzyme A and kill activated CD4+ and CD8+ Tc e l l s
throughaperforin-dependentmechanism,whileFasligation
has been demonstrated not to be involved [57, 58]. In addi-
tion, Tregs prevent DC maturation and activation through
secretion of cytokines, both in mice and men. For this, IL-
10 impairs the antigen-presenting capacity by downregulat-
ing MHC class II and costimulatory molecules on DCs [59].
TGF-β also downregulates MHC class II expression and pre-
vents upregulation of costimulatory molecules [60, 61]. In
addition, CD8+ suppressor cells, from healthy volunteers as
well as transplant patients, have also been shown to inhibit
upregulation of costimulatory molecules (CD80/CD86) on
DCsand,importantly,increasetheexpressionofIg-liketran-
scripts 3 (ILT3) and ILT4 on DCs [62]. These ILT molecules
belong to the family of Ig-like inhibitory receptors and they
arefunctionallyrelatedtokillercellinhibitoryreceptors.Lig-
ation of ILT in antigen-presenting cells inhibits Ca2+ mo-
bilization and tyrosine phosphorylation [63–65]. Moreover,
such ILT-expressing DCs were shown to convert CD4+ allo-
reactiveTcellstowardsTregswithimmunesuppressivefunc-
tion [66].
4. REGULATORY T CELLS IN HUMAN DISEASE
4.1. Autoimmunity
Reduced functional activity of Tregs results in an increased
susceptibility to autoimmune disease. Patients with multi-
ple sclerosis (MS) [67] ,p o l y g l a n d u l a rs y n d r o m eo ft y p eI I
[68], active rheumatoid arthritis (RA) [69], type-I diabetes
[70], psoriasis [71], and myasthenia graves [72] show a sig-
niﬁcant decrease in the suppressive function of CD4+CD25+
Tregs as compared with cells from healthy donors. Because
the percentage of CD4+CD25+ Tregs in peripheral blood of
these patients is unaltered as compared with healthy con-
trols, it has been suggested that it is mainly defective Treg
function, rather than its number, that contributes to dis-
ease development in these disease conditions. In addition, in
some autoimmune diseases, reduced levels of CD4+CD25+
Tregs have been observed in the peripheral blood of patients
[73, 74]. However, in these cases, the recruitment or migra-
tion of Tregs from the blood to the inﬂammatory site may
be responsible for the decreased number of Tregs in periph-
eral blood. Indeed, studies on patients with RA or juvenile
idiopathic arthritis (JIA) demonstrated that at the site of
inﬂammation (i.e., in the synovial ﬂuid) the percentage of4 Clinical and Developmental Immunology
Table 1: Diﬀerent subsets of regulatory T cells.
Cell type Phenotype Suggested immunosuppressive mechanism
CD4+ regulatory T cells
Thymic-derived naturally CD4+CD25+FOXP3+
Cell-cell contact-dependent in vitro (CTLA-4); cell-cell
contact- and cytokine-dependent in vivo (IL-10 and
TGF-β)
occurring Treg
Peripheral-induced naturally CD4+CD25+FOXP3+
occurring Treg
Tr1 cells CD4+CD25±FOXP3−IL-10hi Cell-cell contact
Cytokine-mediated (IL-10 production)
Th3 cells CD4+CD25±FOXP3−TGF-βhi Cytokine-mediated (TGF-β production)
TGF-β/IL-10 double-positive CD4+ Treg TGF-β/IL-10 double-positive Cytokine-mediated (IL-10)
CD4+CD25−FOXP3− and (TGF-β production)
CD8+ regulatory T cells
T suppressor cells (Ts) CD8+CD28− Cell-cell contact-dependent (CTLA-4)
I L - 1 0p r o d u c i n gC D 8Tc e l l s C D 8 +IL-10+ Cytokine-mediated (IL-10 production)
CD4+CD25+ Tregs was signiﬁcantly increased as compared
with the percentage in peripheral blood [75].
In addition to the autoimmune diseases described above,
in allergic patients there is strong evidence for a dysfunction
of CD4+CD25+ Tregs in suppressing Th2 responses [76, 77].
In individuals with allergic or asthmatic disease, a decrease
and/or dysfunction of IL-10 secreting Tr1 cells was observed
as compared to healthy individuals [78–81].
4.2. Cancer
Although the physiological function of Tregs is central for
maintaining self-tolerance, this negative regulatory activity
can also be counterproductive as Tregs might also suppress
bonaﬁde immune responses against tumors and viral infec-
tions. High numbers of CD4+CD25+ Tregs have been found
in lung, pancreas , breast, liver, and skin cancer patients, ei-
ther in the peripheral blood or around and within the tumor
[82–86]. Moreover, Tregs isolated from tumors of lung can-
cer patients demonstrated potent immune suppressive activ-
ity of autologous peripheral blood T cells stimulated by anti-
CD3 or anti-CD3/anti-CD28 in vitro [87]. Therefore, it can
be postulated that Tregs can impair antitumor immune re-
sponses in cancer patients. In addition to naturally occurring
CD4+CD25+ Tregs, also IL-10 producing Tr1 cells have been
demonstratedtocontributetoineﬀectiveantitumorimmune
responses in cancer patients [88, 89]. In human ovarian tu-
mors, it is demonstrated that plasmacytoid DCs induce IL-
10 secreting CD8+ regulatory T cells capable of suppress-
ing antitumor immunity through IL-10 [90]. In addition,
Curiel et al. [91] described that tumor cells and surround-
ing macrophages produce the CCL22 chemokine, which me-
diates Treg-traﬃcking to the tumor through CCR4, thereby
possibly contributing to the immune privileged features of
these tumors. This observation was recently also conﬁrmed
in B cell non-Hodgkin lymphomas [92]. Furthermore, it is
now believed that increased frequencies of Tregs in cancer
patients are associated with a high mortality and reduced
disease-free survival [93–95].
4.3. Infectiousdiseases
Several studies have also reported involvement of Tregs in
infectious diseases, as Tregs might aﬀect the magnitude of
the immune response and therefore the outcome of viral
clearance [96]. Indeed, after depletion of Tregs by anti-CD25
antibody in herpes simplex virus (HSV) infected mice, in-
creased CD4+ T cell responses, enhanced CD8+ proliferative
and cytotoxic T cell responses, and increased mucosal anti-
body levels were reported as compared to nondepleted an-
imals [97, 98]. In addition, viral clearance occurred more
rapidly in Treg-depleted mice [99]. In humans with chronic
hepatitis B virus (HBV) and HCV infection, an increase in
peripheral CD4+CD25+ Tregs, as compared to healthy indi-
viduals, has been described [100, 101]. Moreover, these Tregs
are able to suppress HCV-speciﬁc CD8+ Tc e l li m m u n er e -
sponses [102, 103]. Besides increased levels of Tregs in pa-
tients, IL-10 producing Tr1 cells could also be isolated and
cloned from patients with chronic HCV infection, but not
from patients who cleared the infection [104].
Following the demonstration of the role of Tregs in sup-
pressing antiviral immune responses, several in vitro studies
showed that depletion of Tregs from peripheral blood of vi-
rally infected patients results in increased T cell responses to
HBV, HCV, cytomegalovirus (CMV), and human immun-
odeﬁciency virus (HIV) [105, 106]. While the presented re-
sults are clear for HBV, HCV, and CMV infections, the in-
ﬂuence of Tregs during HIV infection might be more com-
plex. The data provided so far do not provide conclusive ev-
idence whether Tregs in HIV-infected individuals limit or
contribute to immune activation, which results in immune
dysfunction. On the one hand, the frequency of Tregs in-
versely correlates with the magnitude of SIV/HIV-speciﬁc
CTLresponses[105,107].Moreover,patientswithlong-term
nonprogressing disease have low numbers of Tregs in dif-
ferent lymphoid compartments, further supporting the no-
t i o nt h a tT r e g sp r e v e n te ﬃcient anti-HIV responses [108].
On the other hand, the number of circulating Tregs has also
been reported to be decreased in chronically HIV-infectedNathalie Cools et al. 5
patients, and this correlates with hyperactivation [109, 110].
This observed decrease of Treg frequency in blood can be
due to altered traﬃcking and/or accumulation of Tregs into
lymphoid tissues, and it warrants further investigation [108,
111].
5. MANIPULATING REGULATORY T CELLS FOR
THERAPEUTIC APPLICATIONS
The observations mentioned above have therapeutic impli-
cations for targeting Tregs in human disease. Most advanced
studies regarding this topic have been performed in the ﬁeld
of autoimmunity, where the challenge is to enhance Treg re-
sponses against those self-antigens involved in disease pro-
gression. Moreover, it is clear that experimental strategies to
activate and expand self-reactive Tregs in order to dimin-
ish tissue damage may also be applicable to control virus-
induced immune pathology or to inhibit transplant graft re-
jection. Alternatively, limiting or preventing Treg responses
wouldbe requiredtoenhanceinsuﬃcientimmune responses
against certain viral antigens and tumor-associated antigens
(TAAs). Below we discuss several possibilities to manipulate
Treg function in vitro and in vivo.
5.1. Treg-inducingtherapies
Nonspeciﬁc (experimental) therapies using antibodies and
anti-inﬂammatorycytokineshavebeendocumentedtomod-
ify Treg function. For example, treatment with inﬂiximab
(anti-TNF-α) inRAwasabletorestorethedefectivesuppres-
sive function of Tregs and to increase the number of periph-
eral Tregs [69]. Also, administration of nonmitogenic anti-
CD3 monoclonal antibodies [112] and immunomodulatory
cytokines, such as TGF-β [113], are Treg-modulating strate-
gies currently under investigation. Several in vitro studies
have revealed a role for costimulation through CD28 to pro-
mote Treg proliferation [114, 115]. In support of this con-
cept, superagonistic anti-CD28 antibodies, which probably
cause augmented CD28 signaling, are particularly eﬀective
at supporting Treg expansion in vivo [116, 117]. However, it
is worth remembering that these antibodies, when tested in
six healthy volunteers in a clinical trial, sent all these healthy
male subjects to critical care, unlike two additional partici-
pants who had received a placebo. What probably happened
is that, since CD28 receptors are found on diﬀerent cells of
the immune system, this may have caused mass activation of
the immune system, causing a devastating “cytokine storm”
[118, 119].
Although only the antigen-nonspeciﬁc approaches yield-
ed clinical beneﬁt so far, the dramatic outcome of the clin-
ical trial mentioned above or the risk of opportunistic in-
fections using such antigen-nonspeciﬁc strategies might be-
comeproblematic.Therefore,currentresearchfocusesonthe
developmentofnovelantigen-speciﬁcTregtherapiesinorder
to reduce or prevent immune-mediated pathologies by se-
lective enhancement of antigen-speciﬁc Treg populations in
vitro or in vivo. Recent studies have investigated the poten-
tial to isolate CD4+CD25+ Tregs from peripheral blood and
to (antigen-nonspeciﬁcally) expand them in vitro for sub-
sequent adoptive transfer in patients, in order to modulate
ongoing immune responses in vivo. These expanded cells re-
tained expression of CD25, FOXP3,and lymph node homing
receptors. Moreover, such in vitro expanded Tregs appeared
to be more eﬃcient in in vitro suppression assays as com-
paredtofreshlyisolatedTregs[120,121].Inaddition,invitro
expansion protocols for Tregs can be combined with strate-
gies to generate antigen-speciﬁc artiﬁcial Tregs. In this con-
text, Mekala and Geiger [122] described that genetic mod-
iﬁcation of polyclonal Tregs with a chimeric receptor con-
sisting of a myelin basic protein (MBP) epitope bound to
the extracellular and transmembrane domains of an MHC
linked to the cytoplasmic domain of the TCR ζ-chain results
in functional Treg activation upon recognition of these mod-
iﬁed Tregs by MBP-speciﬁc T cells. These receptor-modiﬁed
CD4+CD25+ Tregs inhibited both the onset and the de-
velopment of experimental autoimmune encephalomyelitis
(EAE). This inhibition only occurred when EAE was induced
byMBP,butnotbyanyotherknownEAEautoantigen.While
the strategy described above alters the fundamental mecha-
nism of Treg biology, Jaeckel et al. [123] developed another
strategy based on transduction of naive CD4+ Tc e l l sf r o m
nonobese diabetic (NOD) mice with FOXP3, the trancrip-
tion factor associated with Treg development and function.
These FOXP3-transduced CD4+ T cells produce IL-10 and
they are able to suppress CD4+ T cell proliferation. How-
ever,atherapeuticeﬀectwasonlyobservedwhenFOXP3was
transduced in T cells from TCR transgenic mice that recog-
nize a pancreatic islet antigen. Again, this indicates that anti-
gen speciﬁcity of Tregs will be important for therapeutic eﬃ-
cacy.
Next to genetic modiﬁcation of T cells, in order to ob-
tain antigen-speciﬁc artiﬁcial Tregs, the fact that CD4+-
CD25+FOXP3+ Tregs can also be generated in the periph-
ery might have important clinical implications as no clear
phenotypic orfunctionaldiﬀerenceshavebeenobservedthat
distinguish them from thymic-derived Tregs [21, 124, 125].
In this context, it has been demonstrated in several stud-
ies that DCs can induce diﬀerent subsets of Tregs. More-
over, it has been demonstrated that tolerogenic DCs loaded
with speciﬁc antigen in combination with IL-2 are able to ex-
pand antigen-speciﬁc Tregs ex vivo [114, 126–128]. Alterna-
tively, in vivo targeting of DCs in a steady-state condition by
anti-DEC-205 antibody preferentially increases the number
ofCD4+CD25+ Tregs [129,130].Importantly,suchstrategies
require that DCs remain in their tolerogenic state in order to
prevent immune activation. The latter is currently a subject
of major interest.
5.2. Treg-depletingstrategies
As mentioned above, limiting or preventing Treg responses
might be desired to enhance insuﬃcient immune responses
against certain viral and tumor antigens. Elimination of
Tregs by CD25+ T cell depletion with ONTAK has recently
been evaluated in clinical trials. ONTAK or denileukin difti-
toxisaligand-toxinfusionproteinthatconsistsoffull-length
IL-2 fused to the translocating and enzymatically active do-
mainofdiphtheria toxin[131].Severalstudiesdemonstrated6 Clinical and Developmental Immunology
that administration of ONTAK in cancer patients results in
reduced prevalence of peripheral Tregs and increased eﬀector
Tc e l la c t i v a t i o n[ 132–134]. Moreover, Dannull et al. [132]
showed that administration of ONTAK combined with vac-
cination, with DCs transfected with total tumor RNA, led
to improved stimulation of tumor-speciﬁc eﬀector T cells as
compared to DC vaccination alone.
However, because of their nonexclusive phenotype, de-
pletion of Tregs in vivo is diﬃcult to achieve and may also
lead to severe autoimmune complications (“collateral dam-
age” [135]). Therefore, interfering with Treg activity would
bea moreappropriate strategy.Enhancedimmune responses
have been observed after addition of anti-GITR antibodies.
Ligation of GITR on Tregs results in abrogation of their sup-
pressive function [136]. Moreover, ligation of GITR on ef-
fector T cells provides eﬀector T cells with additional cos-
timulation and makes them refractory to the suppressive ef-
fects of Tregs [137, 138]. Alternatively, it has been demon-
strated that anti-CTLA-4 antibody inhibits the suppressive
activity of Tregs in patients with malignant melanoma. Ef-
fective reduction in tumor mass was shown in approximately
20% of patients. Interestingly, reduction of tumor size was
linked to the development of severe, but manageable, au-
toimmune syndromes [41–44]. However, in cancer patients
treated with the anti-CTLA-4 antibody, no eﬀect was ob-
served on the number or the suppressive activity of periph-
eral blood Tregs. This indicates that CTLA-4 signaling might
represent a regulatory mechanism independent, at least in
part, of Tregs [139]. Moreover, it is also demonstrated that
both mechanisms, Treg depletion and CTLA-4 blockade, can
work synergistically [140] on enhancing antitumor immu-
nity in experimental B16 melanoma.
Finally, another potential strategy to interfere with Treg
function is to target molecules involved in Treg traﬃcking.
BlockingCCL22hasbeenproposedtoreduceTregtraﬃcking
in ovarian cancer in order to prevent their inhibitory func-
tion on APCs and on tumor-speciﬁc T cells [91].
6. CONCLUSIONS
Since the reappraisal of suppressor T cells by the pioneer-
ing work of Sakaguchi et al. [3], the ﬁeld of immune control
by Tregs has been progressing exponentially. Despite recent
advances, several major questions remain regarding their in-
teractions with other cells of the immune system, leading to
their suppressive activity. The quest for more speciﬁc mark-
ers on naturally occurring or induced Tregs will ultimately
lead to improved methods to isolate and functionally char-
acterize these Treg subsets. Better insights will then improve
the design of new and better immunotherapies that should
be able to (i) antigen-speciﬁcally enhance immune responses
against pathogens and tumors or (ii) antigen-speciﬁcally ab-
rogateimmuneresponsesagainstself-antigensorcellandor-
gan transplants.
ACKNOWLEDGMENTS
This work was supported by Grants no. G.0456.03, no.
G.0313.01, and no. WO.012.02 of the Fund for Scientiﬁc Re-
search, Flanders, Belgium (FWO-Vlaanderen), by grants of
the Fortis Bank Verzekeringen, ﬁnanced cancer research, by
research grants of the Foundation Against Cancer (Belgis-
che Federatie tegen Kanker, now Stichting tegen Kanker), by
Grant no. 802 of the Antwerp University Concerted Research
Action(BOF-GOA),andbyaninteruniversityattractionpole
(IAP) grant of the Belgian Science Policy. V. Tendeloo and
P. Ponsaerts are postdoctoral fellows of the Fund for Scien-
tiﬁc Research (FWO-Vlaanderen). N. Cools held a Ph.D. fel-
lowship of the Flemish Institute for Science and Technology
(IWT).
REFERENCES
[1] R. K. Gershon and K. Kondo, “Infectious immunological tol-
erance,” Immunology, vol. 21, no. 6, pp. 903–914, 1971.
[ 2 ]R .K .G e r s h o n ,p .C o h e n ,R .H e n c i n ,a n dS .A .L i e b h a b e r ,
“Suppressor T cells,” Journal of Immunology, vol. 108, pp.
586–590, 1972.
[3] S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda,
“Immunologic self-tolerance maintained by activated T cells
expressing IL-2 receptor α-chains (CD25). Breakdown of a
single mechanism of self-tolerance causes various autoim-
mune diseases,” Journal of Immunology, vol. 155, no. 3, pp.
1151–1164, 1995.
[4] H.JonuleitandE.Schmitt,“TheregulatoryTcellfamily:dis-
tinctsubsetsandtheirinterrelations,”JournalofImmunology,
vol. 171, no. 12, pp. 6323–6327, 2003.
[5] S.Sakaguchi,“RegulatoryTcells:keycontrollersofimmuno-
logic self-tolerance,” Cell, vol. 101, no. 5, pp. 455–458, 2000.
[6] S. Sakaguchi, “Naturally arising Foxp3-expressing
CD25+CD4+ regulatory T cells in immunological toler-
ance to self and non-self,” Nature Immunology, vol. 6, no. 4,
pp. 345–352, 2005.
[7] S. Hori, T. Nomura, and S. Sakaguchi, “Control of regula-
tory T cell development by the transcription factor Foxp3,”
Science, vol. 299, no. 5609, pp. 1057–1061, 2003.
[8] J. D. Fontenot and A. Y. Rudensky, “A well adapted regula-
torycontrivance:regulatoryTcelldevelopmentandthefork-
head familytranscriptionfactorFoxp3,” NatureImmunology,
vol. 6, no. 4, pp. 331–337, 2005.
[9] R. S. Wildin and A. Freitas, “IPEX and FOXP3: clinical and
research perspectives,” Journal of Autoimmunity, vol. 25, sup-
plement, pp. 56–62, 2005.
[10] R. S. Wildin, S. Smyk-Pearson, and A. H. Filipovich, “Clin-
ical and molecular features of the immunodysregulation
, polyendocrinopathy, enteropathy, X linked (IPEX) syn-
drome,” Journal of Medical Genetics, vol. 39, no. 8, pp. 537–
545, 2002.
[ 1 1 ] J .D .F o n t e n o t ,M .A .G a vi n ,a n dA .Y .R u d e n s k y ,“ F o x p 3p r o -
grams the development and function of CD4+CD25+ regula-
tory T cells,” Nature Immunology, vol. 4, no. 4, pp. 330–336,
2003.
[12] A. Y. Rudensky, M. Gavin, and Y. Zheng, “FOXP3 and NFAT:
partnersintolerance,”Cell,vol.126,no.2,pp.253–256,2006.
[13] E. Bettelli, M. Dastrange, and M. Oukka, “Foxp3 interacts
with nuclear factor of activated T cells and NF-κ to repress
cytokine gene expression and eﬀector functions of T helper
cells,” Proceedings of the National Academy of Sciences of the
United States of America , vol. 102, no. 14, pp. 5138–5143,
2005.Nathalie Cools et al. 7
[14] Y.Wu,M.Borde,V.Heissmeyer,etal.,“FOXP3controlsregu-
latory T cell function through cooperation with NFAT,” Cell,
vol. 126, no. 2, pp. 375–387, 2006.
[15] J.Wang,A.Ioan-Facsinay,E.I.vanderVoort,T.W.Huizinga,
and R. E. Toes, “Transient expression of FOXP3 in human
activated nonregulatory CD4+ Tc e l l s , ”European Journal of
Immunology, vol. 37, no. 1, pp. 129–138, 2007.
[16] Y. J. Liu, V. Soumelis, N. Watanabe, et al., “TSLP: an epithe-
lial cell cytokine that regulates T cell diﬀerentiation by con-
ditioning dendritic cell maturation,” Annual Review of Im-
munology, vol. 25, pp. 193–219, 2007.
[17] N. Watanabe, Y. H. Wang, H. K. Lee, et al., “Hassall’s cor-
puscles instruct dendritic cells to induce CD4+CD25+ regu-
latory T cells in human thymus,” Nature, vol. 436, no. 7054,
pp. 1181–1185, 2005.
[18] F. Ramsdell, “Foxp3 and natural regulatory T cells: key to a
cell lineage?” Immunity, vol. 19, no. 2, pp. 165–168, 2003.
[19] F. F. Shih, L. Mandik-Nayak, B. T. Wipke, and P. M. Allen,
“Massive thymic deletion results in systemic autoimmunity
througheliminationofCD4+CD25+ Tr egulat oryc ells, ”Jour-
nal of Experimental Medicine, vol. 199, no. 3, pp. 323–335,
2004.
[20] H. Bagavant, C. Thompson, K. Ohno, Y. Setiady, and K. S.
Tung, “Diﬀerential eﬀect of neonatal thymectomy on sys-
temic and organ-speciﬁc autoimmune disease,” International
Immunology, vol. 14, no. 12, pp. 1397–1406, 2002.
[21] M. Vukmanovic-Stejic, Y. Zhang, J. E. Cook, et al., “Human
CD4+CD25hiFoxp3+ regulatory T cellsare derived by rapid
turnover of memory populations in vivo,” Journal of Clinical
Investigation, vol. 116, no. 9, pp. 2423–2433, 2006.
[22] M. G. Roncarolo, S. Gregori, M. Battaglia, R. Bacchetta, K.
Fleischhauer, and M. K. Levings, “Interleukin-10-secreting
type 1 regulatory T cells in rodents and humans,” Immuno-
logical Reviews, vol. 212, no. 1, pp. 28–50, 2006.
[23] M. G. Roncarolo, R. Bacchetta, C. Bordignon, S. Narula , and
M.K.Levings, “Type 1 Tregulatorycells,” Immunological Re-
views, vol. 182, no. 1, pp. 68–79, 2001.
[24] H. L. Weiner, “Oral tolerance: immune mechanisms and
thegenerationofTh3-typeTGF-β-secretingregulatorycells,”
Microbes and Infection, vol. 3, no. 11, pp. 947–954, 2001.
[25] A. M. Faria and H. L. Weiner, “Oral tolerance and TGF-β-
producing cells,” Inﬂammation & Allergy Drug Targets, vol. 5,
no. 3, pp. 179–190, 2006.
[26] A.H.Enk,“Dendriticcellsintoleranceinduction,”Immunol-
ogy Letters, vol. 99, no. 1, pp. 8–11, 2005.
[27] M.Stassen,S.Fondel, T.Bopp,et al., “Human CD25+ regula-
tory T cells: two subsets deﬁned by the integrins α4β7 or α4β1
confer distinct suppressive properties upon CD4+ Th e l p e r
cells,” European Journal of Immunology, vol. 34, no. 5, pp.
1303–1311, 2004.
[ 2 8 ] N .C o o l s ,V .F .I .V a nT e n d e l o o ,E .L .S m i t s ,e ta l . ,“ I m m u n o -
suppression induced by immature dendritic cells is mediated
by TGF-β/IL-10 double-positive CD4+ regulatory T cells,”
2007,toappearinJournalofCellularandMolecularMedicine.
[29] N. Najaﬁan, T. Chitnis, A. D. Salama, et al., “Regulatory
functions of CD8+CD28
− T cells in an autoimmune disease
model,” Journal of Clinical Investigation, vol. 112, no. 7, pp.
1037–1048, 2003.
[30] L. Scotto, A. J. Naiyer, S. Galluzzo, et al., “Overlap be-
tween molecular markers expressed by naturally occur-
ring CD4+CD25+ regulatory T cells and antigen speciﬁc
CD4+CD25+ and CD8+CD28
− T suppressor cells,” Human
Immunology, vol. 65, no. 11, pp. 1297–1306, 2004.
[31] S. Jiang, S. Tugulea, G. Pennesi, et al., “Induction of MHC-
class I restricted human suppressor T cells by peptide prim-
ing in vitro,” Human Immunology, vol. 59, no. 11, pp. 690–
699, 1998.
[32] X. L. Tang, T. R. Smith, and V. Kumar, “Speciﬁc control of
immunity by regulatory CD8 T cells,” Cellular & Molecular
Immunology, vol. 2, no. 1, pp. 11–19, 2005.
[33] C. Zhang, J. Zhang, and Z. Tian, “The regulatory eﬀect of
naturalkillercells:do“NK-regcells”exist?”Cellular&Molec-
ular Immunology, vol. 3, no. 4, pp. 241–254, 2006.
[34] E. M. Shevach, “CD4+CD25+ suppressor T cells: more ques-
tions than answers,” Nature Reviews Immunology, vol. 2,
no. 6, pp. 389–400, 2002.
[35] E. M. Shevach, R. S. McHugh, C. A. Piccirillo, and A. M.
Thornton, “Control of T-cell activation by CD4+CD25+ sup-
pressor T cells,” Immunological Reviews, vol. 182, pp. 58–67,
2001.
[36] S. Paust, L. Lu, N. McCarty, and H. Cantor, “Engagement
of B7 on eﬀe c t o rTc e l l sb yr e g u l a t o r yTc e l l sp r e v e n t sa u -
toimmune disease,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 101, no. 28, pp.
10398–10403, 2004.
[37] F. Fallarino, U. Grohmann, K. W. Hwang, et al., “Modula-
tion of tryptophan catabolism by regulatory T cells,” Nature
Immunology, vol. 4, no. 12, pp. 1206–1212, 2003.
[38] D. H. Munn, M. D. Sharma, J. R. Lee, et al., “Potential
regulatory function of human dendritic cells expressing in-
doleamine 2,3-dioxygenase,” Science, vol. 297, no. 5588, pp.
1867–1870, 2002.
[39] A. L. Mellor and D. H. Munn, “IDO expression by dendritic
cells: tolerance and tryptophan catabolism,” Nature Reviews
Immunology, vol. 4, no. 10, pp. 762–774, 2004.
[40] S. Read, V. Malmstrom, and F. Powrie, “Cytotoxic T
lymphocyte-associated antigen 4 plays an essential role in
the function of CD25+CD4+ regulatory cells that control
intestinal inﬂammation,” Journal of Experimental Medicine,
vol. 192, no. 2, pp. 295–302, 2000.
[41] J. A. Blansﬁeld, K. E. Beck, K. Tran, et al., “Cyto-
toxic T-lymphocyte-associated antigen-4 blockage can in-
duce autoimmune hypophysitis in patients with metastatic
melanoma and renal cancer,” Journal of Immunotherapy,
vol. 28, no. 6, pp. 593–598, 2005.
[42] A. V. Maker, G. Q. Phan, P. Attia, et al., “Tumor regres-
sion and autoimmunity in patients treated with cytotoxic
T lymphocyte-associated antigen 4 blockade and interleukin
2: a phase I/II study,” Annals of Surgical Oncology, vol. 12,
no. 12, pp. 1005–1016, 2005.
[43] A. V. Maker, J. C. Yang, R. M. Sherry, et al., “Intrapatient
dose escalation of anti-CTLA-4 antibody in patients with
metastatic melanoma,” Journal of Immunotherapy, vol. 29,
no. 4, pp. 455–463, 2006.
[44] G. Q. Phan, J. C. Yang, R. M. Sherry, et al., “Cancer regres-
sion and autoimmunity induced by cytotoxic T lymphocyte-
associated antigen 4 blockade in patients with metastatic
melanoma,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 100, no. 14, pp. 8372–
8377, 2003.
[ 4 5 ]Q .T a n g,E .K .B o d e n ,K .J .H e n r i k s e n ,H .B o u r - j o r d a n ,M .
Bi, and J. A. Bluestone, “Distinct roles of CTLA-4 and TGF-β8 Clinical and Developmental Immunology
in CD4+CD25+ regulatory T cell function,” European Journal
of Immunology, vol. 34, no. 11, pp. 2996–3005, 2004.
[46] T. Takahashi, T. Tagami, S. Yamazaki, et al., “Immunologic
self-tolerance maintained by CD25+CD4+ regulatory T cells
constitutively expressing cytotoxic T lymphocyte-associated
antigen 4,” Journal of Experimental Medicine, vol. 192, no. 2,
pp. 303–310, 2000.
[47] K. Nakamura, A. Kitani, and W. Strober, “Cell contact-
dependent immunosuppression by CD4+CD25+ regulatory
T cells is mediated by cell surface-bound transforming
growth factor β,” Journal of Experimental Medicine, vol. 194,
no. 5, pp. 629–644, 2001.
[48] A. Sundstedt, E. J. O’Neill, K. S. Nicolson, and D. C. Wraith,
“Role for IL-10 in suppression mediated by peptide-induced
regulatory T cells in vivo,” Journal of Immunology, vol. 170,
no. 3, pp. 1240–1248, 2003.
[49] P. L. Vieira, J. R. Christensen, S. Minaee, et al., “IL-
10-secreting regulatory T cells do not express Foxp3 but
have comparable regulatory function to naturally occur-
ring CD4+CD25+ regulatory T cells,” Journal of Immunology,
vol. 172, no. 10, pp. 5986–5993, 2004.
[50] A. O’Garra and P. Vieira, “Regulatory T cells and mecha-
nisms of immune system control,” Nature Medicine, vol. 10,
pp. 801–805, 2004.
[51] A. Taylor, J. Verhagen, K. Blaser, M. Akdis, and C. A. Akdis,
“Mechanisms of immune suppression by interleukin-10 and
transforming growth factor-β : the role of T regulatory cells,”
Immunology, vol. 117, no. 4, pp. 443–442, 2006.
[52] M. K. Levings, R. Bacchetta, U. Schulz, and M. G. Roncar-
olo, “The role of IL-10 and TGF-β in the diﬀerentiation and
eﬀector function of T regulatory cells,” International Archives
ofAllergyandImmunology,vol.129,no.4,pp.263–276,2002.
[53] N. J. Davidson, M. M. Fort, W. M¨ uller, M. W. Leach, and D.
M. Rennick , “Chronic colitis in IL-10-/- mice: insuﬃcient
counter regulation of a Th1 response,” International Reviews
of Immunology, vol. 19, no. 1, pp. 91–121, 2000.
[54] O. Annacker, C. Asseman, S. Read, and F. Powrie,
“Interleukin-10 in the regulation of T cell-induced colitis,”
Journal of Autoimmunity, vol. 20, no. 4, pp. 277–279, 2003.
[55] Y. Matsumoto, T. G. Blanchard, M. L. Drakes, et al., “Eradi-
cation of Helicobacter pylori and resolution of gastritisin the
gastric mucosa of IL-10-deﬁcient mice,” Helicobacter, vol. 10,
no. 5, pp. 407–415, 2005.
[56] S. You, N. Thieblemont, M. A. Alyanakian, J. F. Bach, and
L. Chatenoud, “Transforming growth factor-β and T-cell-
mediated immunoregulation in the control of autoimmune
diabetes,” Immunological reviews, vol. 212, no. 1, pp. 185–
202, 2006.
[ 5 7 ]W .J .G r o s s m a n ,J .W .V e r b s k y ,W .B a r c h e t ,M .C o l o n n a ,J .P .
Atkinson, and T. J. Ley, “Human T regulatory cells can use
the perforin pathway to cause autologous target cell death,”
Immunity, vol. 21, no. 4, pp. 589–601, 2004.
[ 5 8 ] W .J .G r o s s m a n ,J .W .V e rb s ky ,B .L .T o ll e fs e n ,C .K e m pe r ,J .P .
Atkinson,andT.J.Ley,“Diﬀerentialexpressionofgranzymes
A and B in human cytotoxic lymphocyte subsets and T regu-
latory cells,” Blood, vol. 104, no. 9, pp. 2840–2848, 2004.
[59] K. W. Moore, A. O’Garra, M. R. de Waal, P. Vieira, and T. R.
Mosmann, “Interleukin-10,” Annual Review of Immunology,
vol. 11, pp. 165–190, 1993.
[60] F. Geissmann, P. Revy, A. Regnault, et al., “TGF-β 1 prevents
the noncognate maturation of human dendritic Langerhans
cells,” Journal of Immunology, vol. 162, no. 8, pp. 4567–4575,
1999.
[61] H. Strobl and W. Knapp, “TGF-β1 regulation of dendritic
cells,” Microbes and Infection, vol. 1, no. 15, pp. 1283–1290,
1999.
[62] C. C. Chang, R. Ciubotariu, J. S. Manavalan, et al., “Toler-
ization of dendritic cells by Ts cells: the crucial role of in-
hibitoryreceptorsILT3andILT4,”NatureImmunology,vol.3,
pp. 215–217, 2002.
[63] M. Cella, H. Nakajima, F. Facchetti, T. Hoﬀmann, and M.
Colonna, “ILT receptors at the interface between lymphoid
and myeloid cells,” Current Topics in Microbiology and Im-
munology, vol. 251, pp. 161–166, 2000.
[64] M. Cella, C. Dohring, J. Samaridis, et al., “A novel inhibitory
receptor (ILT3) expressed on monocytes, macrophages, and
dendritic cells involved in antigen processing,” Journal of Ex-
perimental Medicine, vol. 185, no. 10, pp. 1743–1751, 1997.
[65] J.V.RavetchandL.L.Lanier,“Immuneinhibitoryreceptors,”
Science, vol. 290, no. 5489, pp. 84–89, 2000.
[66] J. S. Manavalan, P. C. Rossi, G. Vlad, et al., “High expression
of ILT3 and ILT4 is a general feature of tolerogenic dendritic
cells,” Transplant Immunology, vol. 11, no. 3-4, pp. 245–258,
2003.
[67] V. Viglietta, C. Baecher-Allan, H. L. Weiner, and D. A. Haﬂer,
“Loss of functional suppression by CD4+CD25+ regulatory
T cells in patients with multiple sclerosis,” Journal of Experi-
mental Medicine, vol. 199, no. 7, pp. 971–979, 2004.
[68] M. A. Kriegel, T. Lohmann, C. Gabler, N. Blank, J. R. Kalden,
and H. M. Lorenz, “Defective suppressor function of human
CD4+CD25+ regulatory T cells in autoimmune polyglan-
dular syndrome type II,” Journal of Experimental Medicine,
vol. 199, no. 9, pp. 1285–1291, 2004.
[69] M. R. Ehrenstein , J. G. Evans, A. Singh, et al., “Compro-
mised function of regulatory T cells in rheumatoid arthritis
and reversal by anti-TNFα therapy,” Journal of Experimental
Medicine, vol. 200, no. 3, pp. 277–285, 2004.
[70] S. Lindley, C. M. Dayan, A. Bishop, B. O. Roep, M. Peakman,
andT.I.Tree,“DefectivesuppressorfunctioninCD4+CD25+
T-cells from patients with type 1 diabetes,” Diabetes, vol. 54,
no. 1, pp. 92–99, 2005.
[71] H. Sugiyama, R. Gyulai, E. Toichi, et al., “Dysfunctional
blood and target tissue CD25+CD+
4 high regulatory T cells
in psoriasis: Mechanism underlying unrestrained pathogenic
eﬀector T cell proliferation,” Journal of Immunology, vol. 174,
no. 1, pp. 164–173, 2005.
[72] A. Balandina, S. Lecart, P. Dartevelle, A. Saoudi, and S.
Berrih-Aknin, “Functional defect of regulatory CD4+CD25+
T cells in the thymus of patients with autoimmune myasthe-
nia gravis,” Blood, vol. 105, no. 2, pp. 735–741, 2005.
[73] O. Boyer, D. Saadoun, J. Abriol, et al., “CD4+CD25+ regu-
latory T-cell deﬁciency in patients with hepatitis C-mixed
cryoglobulinemiavasculitis,” Blood,vol.103,no.9,pp.3428–
3430, 2004.
[74] M. S. Longhi, M. J. Hussain, R. R. Mitry, et al., “Functional
study of CD4+CD25+ regulatory T cells in health and au-
toimmune hepatitis,” Journal of Immunology, vol. 176, no. 7,
pp. 4484–4491, 2006.
[ 7 5 ]M .M o t t o n e n ,J .H e i k k i n e n ,L .M u s t o n e n ,P .I s o m a k i ,R .
Luukkainen, and O. Lassila, “CD4+CD25+ Tc e l l sw i t ht h e
phenotypic and functional characteristics of regulatory T
cells are enriched in the synovial ﬂuid of patients withNathalie Cools et al. 9
rheumatoid arthritis,” Clinical ˇ n Experimental Immunology,
vol. 140, no. 2, pp. 360–367, 2005.
[76] E. M. Ling, T. Smith, X. D. Nguyen, et al., “Relation of
CD4+CD25+ regulatoryT-cellsuppressionofallergen-driven
T-cell activation to atopic status and expression of allergic
disease,” The Lancet, vol. 363, no. 9409, pp. 608–615, 2004.
[77] H. Grindebacke, K. Wing, A. C. Andersson, E. Suri-Payer, S.
Rak, and A. Rudin, “Defective suppression of Th2 cytokines
by CD4+CD25+ regulatory T cells in birch allergics during
birch pollen season,” Clinical & Experimental Allergy, vol. 34,
no. 9, pp. 1364–1372, 2004.
[78] M. Akdis, J. Verhagen, A. Taylor, et al., “Immune responses
in healthy and allergic individuals are characterized by a ﬁne
balancebetweenallergen-speciﬁcTregulatory1andThelper
2c ells, ”JournalofExperimentalMedicine,vol.199,no.11,pp.
1567–1575, 2004.
[79] C. M. Hawrylowicz and A. O’Garra, “Potential role of
interleukin-10-secreting regulatory T cells in allergy and
asthma,” Nature Reviews Immunology, vol. 5, no. 4, pp. 271–
283, 2005.
[80] E. Xystrakis, S. Kusumakar, S. Boswell, et al., “Reversing the
defective induction of IL-10-secreting regulatory T cells in
glucocorticoid-resistant asthma patients,” Journal of Clinical
Investigation, vol. 116, no. 1, pp. 146–155, 2006.
[ 8 1 ]D .S .R o b i n s o n ,M .L a r c h e ,a n dS .R .D u r h a m ,“ T r e g sa n d
allergic disease,” Journal of Clinical Investigation, vol. 114,
no. 10, pp. 1389–1397, 2004.
[82] E. Y. Woo, C. S. Chu, T. J. Goletz, et al., “Regulatory
CD4+CD25+ T cells in tumors from patients with early-stage
non-small cell lung cancer and late-stage ovarian cancer,”
Cancer Research, vol. 61, no. 12, pp. 4766–4772, 2001.
[ 8 3 ]A .M .W o l f ,D .W o l f ,M .S t e u r e r ,G .G a s t l ,E .G u n s i l i u s ,a n d
B. Grubeck-Loebenstein, “Increase of regulatory T cells in
the peripheral blood of cancer patients,” Clinical Cancer Re-
search, vol. 9, no. 2, pp. 606–612, 2003.
[84] U. K. Liyanage, T. T. Moore, H.-G. Joo, et al., “Prevalence
of regulatory T cells is increased in peripheral blood and tu-
mor microenvironment of patients with pancreas or breast
adenocarcinoma,” Journal of Immunology, vol. 169, no. 5, pp.
2756–2761, 2002.
[85] M. Viguier, F. Lemaitre, O. Verola, et al., “Foxp3 expressing
CD4+CD25high regulatory T cells are overrepresented in hu-
manmetastaticmelanomalymphnodesandinhibitthefunc-
tion of inﬁltrating T cells,” Journal of Immunology, vol. 173,
pp. 1444–1453, 2004.
[86] L. A. Ormandy, T. Hillemann, H. Wedemeyer, M. P. Manns,
T. F. Greten, and F. Korangy, “Increased populations of regu-
latory T cells in peripheral blood of patients with hepatocel-
lular carcinoma,” Cancer Research, vol. 65, no. 6, pp. 2457–
2464, 2005.
[87] E. Y. Woo, H. Yeh, C. S. Chu, et al., “Cutting edge: regulatory
T cells from lung cancer patients directly inhibit autologous
T cell proliferation,” Journal of Immunology, vol. 168, no. 9,
pp. 4272–4276, 2002.
[88] N. A. Marshall, L. E. Christie, L. R. Munro, et al., “Immuno-
suppressive regulatory T cells are abundant in the reactive
lymphocytes of Hodgkin lymphoma,” Blood, vol. 103, no. 5,
pp. 1755–1762, 2004.
[89] F. Fiore, B. Nuschak, S. Peola, et al., “Exposure to myeloma
cell lysates aﬀects the immune competence of dendritic cells
and favors the induction of Tr1-like regulatory T cells,” Eu-
ropean Journal of Immunology, vol. 35, no. 4, pp. 1155–1163,
2005.
[90] S. Wei, I. Kryczek, L. Zou, et al., “Plasmacytoid dendritic
cells induce CD8+ regulatory T cells in human ovarian carci-
noma,”CancerResearch,vol.65,no.12,pp.5020–5026, 2005.
[91] T. J. Curiel, G. Coukos, L. Zou, et al., “Speciﬁc recruitment of
regulatory T cells in ovarian carcinoma fosters immune priv-
ilegeandpredictsreducedsurvival,”NatureMedicine,vol.10,
no. 9, pp. 942–949, 2004.
[92] Z.-Z. Yang, A. J. Novak, M. J. Stenson, T. E. Witzig, and
S. M. Ansell, “Intratumoral CD4+CD25+ regulatory T-cell-
mediated suppression of inﬁltrating CD4+ Tc e l l si nB - c e l l
non-Hodgkin lymphoma,” Blood, vol. 107, no. 9, pp. 3639–
3646, 2006.
[93] K. Kono, H. Kawaida, A. Takahashi, et al., “CD4+CD25high
regulatory T cells increase with tumor stage in patients
with gastric and esophageal cancers,” Cancer Immunol Im-
munother, vol. 55, no. 9, pp. 1064–1071, 2006.
[94] A. Gallimore and S. Sakaguchi, “Regulation of tumour im-
munity by CD25+ Tc e l l s , ”Immunology, vol. 107, no. 1, pp.
5–9, 2002.
[95] W. Zou, “Immunosuppressive networks in the tumour en-
vironment and their therapeutic relevance,” Nature Reviews
Cancer, vol. 5, no. 4, pp. 263–274, 2005.
[96] B. T. Rouse, P. P. Sarangi, and S. Suvas, “Regulatory T cells
in virus infectionsal,” Immunological Reviews, vol. 212, no. 1,
pp. 272–286, 2006.
[97] S. Suvas, A. K. Azkur, B. S. Kim, U. Kumaraguru, and B. T.
Rouse,“CD4+CD25+ regulatoryTcellscontroltheseverityof
viral immunoinﬂammatory lesions,” Journal of Immunology,
vol. 172, no. 7, pp. 4123–4132, 2004.
[98] S. Suvas, U. Kumaraguru, C. D. Pack, S. Lee, and B. T.
Rouse, “CD4+CD25+ T cells regulate virus-speciﬁc primary
and memory CD8+ T cell responses,” Journal of Experimental
Medicine, vol. 198, no. 6, pp. 889–901, 2003.
[99] F. N. Toka, S. Suvas, and B. T. Rouse, “CD4+CD25+ Tc e l l s
regulate vaccine-generated primary and memory CD8+ T-
cell responses against herpes simplex virus type 1,” Journal
of Virology, vol. 78, no. 23, pp. 13082–13089, 2004.
[100] R. Cabrera, Z. Tu, Y. Xu, et al., “An immunomodulatory
role for CD4+CD25+ regulatory T lymphocytes in hepatitis
C virus infection,” Hepatology, vol. 40, no. 5, pp. 1062–1071,
2004.
[101] J. N. Stoop, R. G. van der Molen, and C. C. Baan, “Regula-
tory T cells contribute to the impaired immune response in
patientswithchronichepatitisBvirusinfection,”Hepatology,
vol. 41, no. 4, pp. 771–778, 2005.
[102] T. Boettler, H. C. Spangenberg, C. Neumann-Haefelin, et
al., “T cells with a CD4+CD25+ regulatory phenotype sup-
pressin vitroproliferationof virus-speciﬁc CD8+ Tc ell sd u r -
ing chronic hepatitis C virus infection,” Journal of Virology,
vol. 79, no. 12, pp. 7860–7867, 2005.
[103] S. M. Rushbrook, S. M. Ward, E. Unitt, et al., “Regulatory T
cells suppress in vitro proliferation of virus-speciﬁc CD8+ T
cells during persistent hepatitis C virus infection,” Journal of
Virology, vol. 79, no. 12, pp. 7852–7859, 2005.
[104] A.J. MacDonald, M. Duﬀy, M. T. Brady, et al., “CD4 T helper
type 1 and regulatory T cells induced against the same epi-
topes on the core protein in hepatitis C virus-infected per-
sons,” Journal of Infectious Diseases, vol. 185, no. 6, pp. 720–
727, 2002.10 Clinical and Developmental Immunology
[105] E. M. Aandahl, J. Michaelsson, W. J. Moretto, F. M. Hecht,
a n dD .F .N i x o n ,“ H u m a nC D 4 +CD25+ regulatory T cells
control T-cell responses to human immunodeﬁciency virus
and cytomegalovirus antigens,” Journal of Virology, vol. 78,
no. 5, pp. 2454–2459, 2004.
[106] L. Weiss, V. Donkova-Petrini, L. Caccavelli, M. Balbo, C.
Carbonneil, and Y. Levy, “Human immunodeﬁciency virus-
driven expansion of CD4+CD25+ regulatory T cells, which
suppress HIV-speciﬁc CD4 T-cell responses in HIV-infected
patients,” Blood, vol. 104, no. 10, pp. 3249–3256, 2004.
[107] J.D.Estes,Q.Li,M.R.Reynolds,etal.,“Prematureinduction
of an immunosuppressive regulatory T cell response during
acute simian immunodeﬁciency virus infection,” Journal of
Infectious Diseases, vol. 193, no. 5, pp. 703–712, 2006.
[108] J. Nilsson, A. Boasso, P. A. Velilla, et al., “HIV-1-driven reg-
ulatory T-cell accumulation in lymphoid tissues is associ-
ated with disease progression in HIV/AIDS,” Blood, vol. 108,
no. 12, pp. 3808–3817, 2006.
[109] K. Oswald-Richter, S. M. Grill, N. Shariat, et al., “HIV in-
fection of naturally occurring and genetically reprogrammed
humanregulatoryT-cells,”PLoSBiology,vol.2,no.7,p.e198,
2004.
[110] M. P. Eggena, B. Barugahare, N. Jones, et al., “Depletion of
regulatoryTcellsinHIVinfectionisassociatedwithimmune
activation,” Journal of Immunology, vol. 174, no. 7, pp. 4407–
4414, 2005.
[111] J. Andersson, A. Boasso, J. Nilsson, et al., “Cutting edge: the
prevalence of regulatory T cells in lymphoid tissue is corre-
lated with viral load in HIV-infected patients,” Journal of Im-
munology, vol. 174, no. 6, pp. 3143–3147, 2005.
[112] M. Belghith, J. A. Bluestone, S. Barriot, J. Megret, J. F. Bach,
and L. Chatenoud, “TGF-β-dependent mechanisms mediate
restoration of self-tolerance induced by antibodies to CD3 in
overt autoimmune diabetes,” Nature Medicine, vol. 9, no. 9,
pp. 1202–1208, 2003.
[113] W. Chen, W. Jin, N. Hardegen, et al., “Conversion of periph-
eral CD4+CD25
−-n a ¨ ıve T cells to CD4+CD25+ regulatory T
cells by TGF-β inductionoftranscriptionfactorFoxp3,”Jour-
nalofExperimentalMedicine,vol.198,no.12,pp.1875–1886,
2003.
[114] S. Yamazaki, T. Iyoda, K. Tarbell, et al., “Direct expansion
of functional CD25+CD4+ regulatory T cells by antigen-
processing dendritic cells,” Journal of Experimental Medicine,
vol. 198, no. 2, pp. 235–247, 2003.
[115] Q. Tang, K. J. Henriksen, E. K. Boden, et al., “Cutting edge:
CD28 controls peripheral homeostasis of CD4+CD25+ reg-
ulatory T cells,” Journal of Immunology, vol. 171, no. 7, pp.
3348–3352, 2003.
[116] C.-H. Lin and T. Hunig, “Eﬃcient expansion of regulatory T
cellsinvitroandinvivowithaCD28superagonist,”European
Journal of Immunology, vol. 33, no. 3, pp. 626–638, 2003.
[117] N. Beyersdorf, S. Gaupp, K. Balbach, et al., “Selective tar-
geting of regulatory T cells with CD28 superagonists al-
lows eﬀective therapy of experimental autoimmune en-
cephalomyelitis,” Journal of Experimental Medicine, vol. 202,
no. 3, pp. 445–455, 2005.
[118] E. Marshall, “Drug trials: violent reaction to monoclonal an-
tibodytherapyremainsamystery,”Science,vol.311,no.5768,
pp. 1688–1689, 2006.
[119] M. Hopkin , “Can super-antibody drugs be tamed?” Nature,
vol. 440, pp. 855–856, 2006.
[120] P. Hoﬀmann, R. Eder, L. A. Kunz-Schughart, R. Andreesen,
andM.Edinger,“Large-scaleinvitroexpansionofpolyclonal
human CD4+CD25high regulatory T cells,” Blood, vol. 104,
no. 3, pp. 895–903, 2004.
[121] W. R. Godfrey, Y. G. Ge, D. J. Spoden, et al., “In
vitro-expanded human CD4+CD25+ T-regulatory cells can
markedly inhibit allogeneic dendritic cell-stimulated MLR
cultures,” Blood, vol. 104, no. 2, pp. 453–461, 2004.
[122] D. J. Mekala and T. L. Geiger, “Immunotherapy of autoim-
muneencephalomyelitis withredirectedCD4+CD25+ Tl ym-
phocytes,” Blood, vol. 105, no. 5, pp. 2090–2092, 2005.
[123] E. Jaeckel, H. von Boehmer, and M. P. Manns, “Antigen-
speciﬁc Foxp3-transduced T-cells can control established
type 1 diabetes,” Diabetes, vol. 54, no. 2, pp. 306–310, 2005.
[124] E. Maggi, L. Cosmi, F. Liotta, P. Romagnani, S. Romagnani,
and F. Annunziato, “Thymic regulatory T cells,” Autoimmu-
nity Reviews, vol. 4, no. 8, pp. 579–586, 2005.
[125] S.Chattopadhyay,N.G.Chakraborty,andB.Mukherji,“Reg-
ulatory T cells and tumor immunity,” Cancer Immunol Im-
munother, vol. 54, no. 12, pp. 1153–1161, 2005.
[126] S. Yamazaki, K. Inaba, K. V. Tarbell, and R. M. Steinman,
“Dendritic cells expand antigen-speciﬁc Foxp3+CD25+CD4+
regulatoryTcellsincludingsuppressorsofalloreactivity,”Im-
munological Reviews, vol. 212, pp. 314–329, 2006.
[127] K. V. Tarbell, S. Yamazaki, K. Olson, P. Toy, and R. M. Stein-
man, “CD25+CD4+ T cells, expanded with dendritic cells
presenting a single autoantigenic peptide, suppress autoim-
mune diabetes,” Journal of Experimental Medicine, vol. 199,
no. 11, pp. 1467–1477, 2004.
[128] Z. Fehervari and S. Sakaguchi, “Control of
Foxp3+CD25+CD4+ regulatory cell activation and function
by dendritic cells,” International Immunology, vol. 16, no. 12,
pp. 1769–1780, 2004.
[129] K. Mahnke, Y. Qian, J. Knop, and A. H. Enk, “Induction of
CD4+/CD25+ regulatory T cells by targeting of antigens to
immature dendritic cells,” Blood, vol. 101, no. 12, pp. 4862–
4869, 2003.
[130] K. Kretschmer, I. Apostolou, D. Hawiger, K. Khazaie, M. C.
Nussenzweig, and H. von Boehmer, “Inducing and expand-
ing regulatory T cell populations by foreign antigen,” Nature
Immunology, vol. 6, no. 12, pp. 1219–1227, 2005.
[131] F. M. Foss, “DAB(389)IL-2 (denileukin diftitox, ONTAK): a
new fusion protein technology,” Clinical Lymphoma, vol. 1,
supplement 1, pp. S27–S31, 2000.
[132] J.Dannull,Z.Su,D.Rizzieri,etal.,“Enhancementofvaccine-
mediated antitumorimmunityincancer patientsafterdeple-
tion of regulatory T cells,” Journal of Clinical Investigation,
vol. 115, no. 12, pp. 3623–3633, 2005.
[133] A. E. Frankel, A. Surendranathan, J. H. Black, A. White, K.
Ganjoo, and L. D. Cripe, “Phase II clinical studies of de-
nileukin diftitox diphtheria toxin fusion protein in patients
with previously treated chronic lymphocytic leukemia,” Can-
cer, vol. 106, no. 10, pp. 2158–2164, 2006.
[134] F. Foss, “Clinical experience with denileukin diftitox (ON-
TAK),” Seminars in Oncology, vol. 33, supplement S3, pp.
S11–S16, 2006.
[135] W.-Z. Wei, J. B. Jacob, J. F. Zielinski, et al., “Concurrent in-
duction of antitumor immunity and autoimmune thyroiditis
in CD4+CD25+ regulatory T cell-depleted mice,” Cancer Re-
search, vol. 65, no. 18, pp. 8471–8478, 2005.
[136] J. Shimizu, S. Yamazaki, T. Takahashi, Y. Ishida, and S.
Sakaguchi, “Stimulation of CD25+CD4+ regulatory T cells
through GITR breaks immunological self-tolerance,” Nature
Immunology, vol. 3, pp. 135–142, 2002.Nathalie Cools et al. 11
[137] E. M. Shevach and G. L. Stephens, “The GITR-GITRL in-
teraction: co-stimulation or contrasuppression of regulatory
activity?” Nature Reviews Immunology, vol. 6, pp. 613–618,
2006.
[138] G. L. Stephens, R. S. McHugh, M. J. Whitters, et al., “En-
gagementofglucocorticoid-inducedTNFRfamily-relatedre-
ceptor on eﬀector T cells by its ligand mediates resistance to
suppression by CD4+CD25+ Tc e l l s , ”Journal of Immunology,
vol. 173, no. 8, pp. 5008–5020, 2004.
[139] P. Atria, G. Q. Phan, A. V. Maker, et al., “Autoimmunity
correlates with tumor regression in patients with metastatic
melanoma treated with anti-cytotoxic T-lymphocyte
antigen-4,” Journal of Clinical Oncology, vol. 23, no. 25, pp.
6043–6053, 2005.
[140] R. P. Sutmuller, L. M. van Duivenvoorde, A. van Elsas, et al.,
“Synergism of cytotoxic T lymphocyte-associated antigen 4
blockade and depletion of CD25+ regulatory T cells in an-
titumor therapy reveals alternative pathways for suppression
of autoreactive cytotoxic T lymphocyte responses,” Journal of
Experimental Medicine, vol. 194, pp. 823–832, 2001.